111 related articles for article (PubMed ID: 14694016)
21. Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study.
Burgos R; Mateo C; Cantón A; Hernández C; Mesa J; Simó R
Diabetes Care; 2000 Jan; 23(1):80-3. PubMed ID: 10857973
[TBL] [Abstract][Full Text] [Related]
22. The angiogenic biomarker endocan is upregulated in proliferative diabetic retinopathy and correlates with vascular endothelial growth factor.
Abu El-Asrar AM; Nawaz MI; De Hertogh G; Al-Kharashi AS; Van den Eynde K; Mohammad G; Geboes K
Curr Eye Res; 2015 Mar; 40(3):321-31. PubMed ID: 24871583
[TBL] [Abstract][Full Text] [Related]
23. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy.
Watanabe D; Suzuma K; Suzuma I; Ohashi H; Ojima T; Kurimoto M; Murakami T; Kimura T; Takagi H
Am J Ophthalmol; 2005 Mar; 139(3):476-81. PubMed ID: 15767056
[TBL] [Abstract][Full Text] [Related]
24. [Analysis of the Cochrane Review: Anti-vascular Endothelial Growth Factor for Prevention of Postoperative Vitreous Cavity Hemorrhage after Vitrectomy for Proliferative Diabetic Retinopathy. Cochrane Database Syst Rev. 2015;8:CD008214.].
Sousa DC; Leal I; Costa J; Vaz-Carneiro A
Acta Med Port; 2017 Aug; 30(7-8):513-516. PubMed ID: 28926323
[TBL] [Abstract][Full Text] [Related]
25. Effects of intravitreal injection of bevacizumab on inflammatory cytokines in the vitreous with proliferative diabetic retinopathy.
Suzuki Y; Suzuki K; Yokoi Y; Miyagawa Y; Metoki T; Nakazawa M
Retina; 2014 Jan; 34(1):165-71. PubMed ID: 23851630
[TBL] [Abstract][Full Text] [Related]
26. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
Qian J; Lu Q; Tao Y; Jiang YR
Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
[TBL] [Abstract][Full Text] [Related]
27. Management of proliferative diabetic retinopathy.
Gündüz K; Bakri SJ
Compr Ophthalmol Update; 2007; 8(5):245-56. PubMed ID: 18201511
[TBL] [Abstract][Full Text] [Related]
28. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy.
Funatsu H; Yamashita H; Nakanishi Y; Hori S
Br J Ophthalmol; 2002 Mar; 86(3):311-5. PubMed ID: 11864890
[TBL] [Abstract][Full Text] [Related]
29. Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy.
Chernykh VV; Varvarinsky EV; Smirnov EV; Chernykh DV; Trunov AN
Indian J Ophthalmol; 2015 Jan; 63(1):33-6. PubMed ID: 25686060
[TBL] [Abstract][Full Text] [Related]
30. [Role of the vitreous body in diabetic retinopathy].
Hendrikse F; Yeo KT
Klin Monbl Augenheilkd; 1993 Nov; 203(5):319-23. PubMed ID: 8114473
[TBL] [Abstract][Full Text] [Related]
31. [Immunodetection of vascular endothelial growth factor in the vitreous of eyes with proliferative diabetic retinopathy].
Ozaki H; Hayashi H; Oshima K; Imanaga Y; Kuroki M; Arakawa F; Kuwahara M; Matsuoka Y
Nippon Ganka Gakkai Zasshi; 1996 Mar; 100(3):208-12. PubMed ID: 8900585
[TBL] [Abstract][Full Text] [Related]
32. Intraocular oxygen distribution in advanced proliferative diabetic retinopathy.
Lange CAK; Stavrakas P; Luhmann UFO; de Silva DJ; Ali RR; Gregor ZJ; Bainbridge JWB
Am J Ophthalmol; 2011 Sep; 152(3):406-412.e3. PubMed ID: 21723532
[TBL] [Abstract][Full Text] [Related]
33. Deficit of somatostatin in the vitreous fluid of patients with diabetic macular edema.
Simó R; Carrasco E; Fonollosa A; García-Arumí J; Casamitjana R; Hernández C
Diabetes Care; 2007 Mar; 30(3):725-7. PubMed ID: 17327350
[No Abstract] [Full Text] [Related]
34. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy.
Hogeboom van Buggenum IM; Polak BC; Reichert-Thoen JW; de Vries-Knoppert WA; van Hinsbergh VW; Tangelder GJ
Diabetologia; 2002 Feb; 45(2):203-9. PubMed ID: 11935151
[TBL] [Abstract][Full Text] [Related]
35. Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy.
Cantón A; Burgos R; Hernández C; Mateo C; Segura RM; Mesa J; Simó R
Br J Ophthalmol; 2000 Jul; 84(7):732-5. PubMed ID: 10873984
[TBL] [Abstract][Full Text] [Related]
36. [The expression of vascular endothelial growth factor of vitreous in patients with proliferative diabetic retinopathy].
Yan H; Cui J; Yu JG; Han JD; Chen S; Zhang JK; Xu YH
Zhonghua Yan Ke Za Zhi; 2009 Mar; 45(3):206-9. PubMed ID: 19575912
[TBL] [Abstract][Full Text] [Related]
37. [Cytokines in the vitreous fluid of patients with proliferative diabetic retinopathy--vascular endothelial growth factor and platelet-derived growth factor are elevated in proliferative diabetic retinopathy].
Endo H; Naito T; Asahara T; Kajima M; Shiota H
Nippon Ganka Gakkai Zasshi; 2000 Oct; 104(10):711-6. PubMed ID: 11081306
[TBL] [Abstract][Full Text] [Related]
38. High vitreous concentration of vascular endothelial growth factor in diabetic patients with proliferative retinopathy using statins.
Liinamaa MJ; Savolainen MJ
Ann Med; 2008; 40(3):209-14. PubMed ID: 18382886
[TBL] [Abstract][Full Text] [Related]
39. Identification of VEGF-independent cytokines in proliferative diabetic retinopathy vitreous.
Bromberg-White JL; Glazer L; Downer R; Furge K; Boguslawski E; Duesbery NS
Invest Ophthalmol Vis Sci; 2013 Oct; 54(10):6472-80. PubMed ID: 24003089
[TBL] [Abstract][Full Text] [Related]
40. Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy.
Wang X; Wang G; Wang Y
Am J Ophthalmol; 2009 Dec; 148(6):883-9. PubMed ID: 19837381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
